Research programme: amyloid precursor protein secretase inhibitors - Astex Pharmaceuticals/AstraZeneca

Drug Profile

Research programme: amyloid precursor protein secretase inhibitors - Astex Pharmaceuticals/AstraZeneca

Alternative Names: AZ-12066871; BACE1 inhibitors - Astex Pharmaceuticals/AstraZeneca; Beta-secretase inhibitors - Astex Pharmaceuticals/AstraZeneca; Memapsin-2 inhibitors - Astex Pharmaceuticals/AstraZeneca

Latest Information Update: 16 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Pharmaceuticals; AstraZeneca
  • Class Pyrimidines; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 01 Jan 2013 Preclinical development is ongoing in United Kingdom
  • 12 Sep 2011 SuperGen is now called Astex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top